SP2509, an inhibitor of LSD1, exerts potential antitumor effects by targeting the JAK/STAT3 signaling

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling is hyperactivated in many cancers, driving tumorigenesis and progression.
• STAT3 is crucial for cancer cell proliferation, survival, and differentiation.
• Targeting the JAK/STAT3 pathway is a promising strategy for cancer therapy.

Purpose of the Study:

• To identify novel inhibitors of the JAK/STAT3 signaling pathway.
• To investigate the anti-cancer effects of SP2509, a newly identified inhibitor.
• To elucidate the mechanism of action of SP2509.

Main Methods:

• High-throughput drug screening using a STAT3-driven luciferase reporter system.
• In vitro assays to assess SP2509's effects on STAT3 activation, downstream gene expression, JAK activity, cell cycle, proliferation, and apoptosis.
• In vivo studies to evaluate SP2509's efficacy in inhibiting tumor growth.
• Analysis of SP2509's mechanism of action, including its interaction with lysine-specific demethylase 1.

Main Results:

• SP2509 potently inhibits constitutive STAT3 activation and downstream gene expression (Bcl-xL, c-Myc, Cyclin D1).
• SP2509 specifically inhibits JAK activity, leading to cell cycle arrest, inhibited growth, and apoptosis in cancer cells.
• SP2509 demonstrates in vivo tumor growth inhibition and in vitro cancer cell death induction.
• SP2509-mediated inhibition of STAT3 phosphorylation is dependent on its target, lysine-specific demethylase 1.

Conclusions:

• SP2509 is a novel and potent inhibitor of the JAK/STAT3 signaling pathway.
• SP2509 exhibits significant anti-cancer activity both in vitro and in vivo.
• SP2509 represents a promising therapeutic candidate for cancers driven by JAK/STAT3 signaling.